Business Context and Reporting Period
This Form 8-K filing by Natera, Inc. (NTRA) reports a material definitive agreement and the creation of a direct financial obligation dated April 13, 2020. The company, incorporated in Delaware and headquartered in San Carlos, California, is an emerging growth company.
Key Financial Metrics and Transaction Details
- Offering Size: $287.5 million aggregate principal amount of 2.25% Convertible Senior Notes due 2027.
- Net Proceeds: Approximately $278.4 million after deducting discounts and estimated offering expenses.
- Interest Rate: 2.25% per annum, payable semiannually in cash beginning November 1, 2020.
- Maturity Date: May 1, 2027.
- Conversion Terms: Initial conversion rate of 25.7785 shares per $1,000 principal amount (approx. $38.79 per share). Maximum potential issuance of 9,634,700 shares of Common Stock.
- Debt Repayment: A portion of proceeds is designated to repay existing debt obligations under a Credit Agreement with OrbiMed Royalty Opportunities II, LP, including accrued interest and pre-payment penalties.
Material Changes and Use of Proceeds
The primary material change is the issuance of new senior unsecured debt. The company intends to use the net proceeds for the following purposes:
- Repayment of existing debt obligations to OrbiMed Royalty Opportunities II, LP.
- Working capital and general corporate purposes.
- Continued investments in research and development.
- Potential acquisitions of complementary businesses, technologies, or assets (no material commitments currently exist).
Outlook, Risks, and Contingencies
Conversion and Redemption: Holders may convert notes prior to February 1, 2027, only under specific circumstances, such as significant price appreciation of the common stock or if the trading price of the notes falls below 98% of the product of the stock price and conversion rate. Upon a "fundamental change," holders may require the company to repurchase notes at 100% of principal plus accrued interest.
Events of Default: The indenture outlines standard events of default, including failure to pay interest or principal, failure to convert notes upon exercise of rights, bankruptcy, and cross-defaults on indebtedness exceeding $20 million.
Management Commentary: The filing does not provide specific forward-looking financial guidance or earnings outlook beyond the stated use of proceeds for R&D and potential acquisitions.
Investor Verification Checklist
- Verify the exact amount of debt repaid to OrbiMed Royalty Opportunities II, LP versus the amount retained for working capital.
- Review the full Indenture (Exhibit 4.1) for specific covenants and restrictions on future indebtedness.
- Monitor the company's stock price relative to the $38.79 conversion price to assess dilution risk.
- Confirm the status of the Credit Agreement with OrbiMed to ensure full satisfaction of the obligation.
- Check for any subsequent filings regarding the exercise of the option to purchase additional notes, if applicable.